Identification of 15 T Cell Restricted Genes Evaluates T Cell Infiltration of Human Healthy Tissues and Cancers and Shows Prognostic and Predictive Potential

T cell gene signatures are used to evaluate T cell infiltration of non-lymphoid tissues and cancers in both experimental and clinical settings. However, some genes included in the available T cell signatures are not T cell-restricted. Herein, we propose a new human T cell signature that has been developed via a six-step procedure and comprises 15 T cell restricted genes. We demonstrate the new T cell signature, named signature-H, that differs from other gene signatures since it shows higher sensitivity and better predictivity in the evaluation of T cell infiltration in healthy tissues as well as 32 cancers. Further, results from signature-H are highly concordant with the immunohistochemistry methods currently used for assessing the prognosis of neuroblastoma, as demonstrated by the Kaplan–Meier curves of patients ranked by tumor T cell infiltration. Moreover, T cell infiltration levels calculated using signature-H correlate with the risk groups determined by the staging of the neuroblastoma. Finally, multiparametric analysis of tumor-infiltrating T cells based on signature-H let us favorably predict the response of melanoma to the anti-PD-1 antibody nivolumab. These findings suggest that signature-H evaluates T cell infiltration levels of tissues and may be used as a prognostic tool in the precision medicine perspective after appropriate clinical validation.

[1]  V. Chan,et al.  Pathogenic role of tissue-resident memory T cells in autoimmune diseases. , 2018, Autoimmunity reviews.

[2]  B. Rini,et al.  Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma , 2018, Medicine.

[3]  Kongming Wu,et al.  Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors , 2018, Molecular Cancer.

[4]  J. Grob,et al.  Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives , 2018, Drugs.

[5]  R. V. van Lier,et al.  Tissue-resident memory T cells at the center of immunity to solid tumors , 2018, Nature Immunology.

[6]  D. Tscharke,et al.  Tissue‐resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance , 2018, Immunological reviews.

[7]  K. Kabashima,et al.  Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations , 2018, Front. Oncol..

[8]  L. Garraway,et al.  TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas , 2018, Oncoimmunology.

[9]  C. Riccardi,et al.  Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis , 2018, Oncoimmunology.

[10]  Javier Martín,et al.  HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape , 2017, Oncotarget.

[11]  C. Criscitiello,et al.  Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. , 2017, Breast.

[12]  Yufeng Shen,et al.  Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites. , 2017, Cell reports.

[13]  Carsten Denkert,et al.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe , 2017, Advances in anatomic pathology.

[14]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.

[15]  A. Kallies,et al.  Transcriptional Regulation of Tissue-Resident Lymphocytes. , 2017, Trends in immunology.

[16]  R. Sackstein,et al.  T-Lymphocyte Homing: An Underappreciated yet Critical Hurdle for Successful Cancer Immunotherapy , 2017, Laboratory investigation; a journal of technical methods and pathology.

[17]  J. Sosman,et al.  Erratum: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell (2016) 165(1) (35–44)(S009286741630215X)(10.1016/j.cell.2016.02.065)) , 2017 .

[18]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[19]  C. Paweletz,et al.  Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. , 2016, JCI insight.

[20]  W. Cooper,et al.  The Role of Tumor‐Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[22]  P. Hegde,et al.  The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition , 2016, Clinical Cancer Research.

[23]  A. Rudensky,et al.  Hallmarks of Tissue-Resident Lymphocytes , 2016, Cell.

[24]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[25]  C. Riccardi,et al.  Modulation of tumor immunity: a patent evaluation of WO2015026684A1 , 2016, Expert opinion on therapeutic patents.

[26]  C. Meijer,et al.  Extent and location of tumor infiltrating lymphocytes in microsatellite stable colon cancer predict outcome to adjuvant active specific immunotherapy , 2015, Journal of Immunotherapy for Cancer.

[27]  Antoni Ribas,et al.  Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.

[28]  Cesare Furlanello,et al.  Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma , 2015, Oncoimmunology.

[29]  Pornpimol Charoentong,et al.  Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy , 2015, Genome Biology.

[30]  G. Brodeur,et al.  Mechanisms of neuroblastoma regression , 2014, Nature Reviews Clinical Oncology.

[31]  Robert Petryszak,et al.  ArrayExpress update—simplifying data submissions , 2014, Nucleic Acids Res..

[32]  Roland Eils,et al.  Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers , 2014, Clinical Cancer Research.

[33]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[34]  Zhandong Liu,et al.  Digital sorting of complex tissues for cell type-specific gene expression profiles , 2013, BMC Bioinformatics.

[35]  R. Seeger Immunology and immunotherapy of neuroblastoma. , 2011, Seminars in cancer biology.

[36]  J. Maris Recent advances in neuroblastoma. , 2010, The New England journal of medicine.

[37]  Peter Widmayer,et al.  Genevestigator V3: A Reference Expression Database for the Meta-Analysis of Transcriptomes , 2008, Adv. Bioinformatics.

[38]  L. Zitvogel,et al.  The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.

[39]  M. Koch,et al.  Tumor Infiltrating T Lymphocytes in Colorectal Cancer: Tumor-Selective Activation and Cytotoxic Activity In Situ , 2006, Annals of surgery.

[40]  I. Lauder,et al.  The Significance of Lymphocytic Infiltration in Neuroblastoma , 1972, British Journal of Cancer.

[41]  Ash A. Alizadeh,et al.  SUPPLEMENTARY NOTE , 1879, Botanical Gazette.

[42]  Masato Takahashi,et al.  The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC) , 2017, Breast Cancer.

[43]  T. Nielsen,et al.  Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication , 2016, Breast Cancer.

[44]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..